Skip directly to site content Skip directly to page options Skip directly to A-Z link Skip directly to A-Z link Skip directly to A-Z link

Disclaimer: Early release articles are not considered as final versions. Any changes will be reflected in the online version in the month the article is officially released.

Volume 32, Number 4—April 2026

Research

Dengue Incidence, Seroprevalence, and Expansion Factors from Active Surveillance, Brazil, 2016–2021

Eliana Nogueira Castro de Barros, Manuela de Almeida Roediger, Maïna L’Azou JacksonComments to Author , Morgan A. Marks, Elizabeth M. Anderson, Alejandra Esteves-Jaramillo, Germán Áñez, José A. Sousa Moreira, and Fernanda Castro Boulos
Author affiliation: Instituto Butantan, São Paulo, Brazil (E.N.C. Barros, M.A. Roediger, J.A.S. Moreira, F.C. Boulos); MSD (UK) Limited, London, UK (M. L'Azou Jackson); Merck & Co., Inc., Rahway, New Jersey, USA (M.A. Marks, E.M. Anderson, A. Esteves-Jaramillo, G. Áñez)

Main Article

Figure 3

Locations of DEN-03-IB clinical study sites and expansion factors by municipality, Brazil, 2016–2021. A) Locations of clinical sites that enrolled participants in the DEN-03-IB phase 3 study of a live attenuated tetravalent dengue vaccine, Butantan-DV, in the 5 geographic regions (North, Northeast, Center-West, Southeast, South). B, C) Expansion factors and 95% CIs by municipality for the entire study period 2016–2021 (B) and during an outbreak year, 2019 (C). Note that 2 clinical sites were located in São Paulo and that Laranjeiras was the municipality closest to the clinical site in Aracaju.

Figure 3. Locations of DEN-03-IB clinical study sites and expansion factors by municipality, Brazil, 2016–2021. A) Locations of clinical sites that enrolled participants in the DEN-03-IB phase 3 study of a live attenuated tetravalent dengue vaccine, Butantan-DV, in the 5 geographic regions (North, Northeast, Center-West, Southeast, South). B, C) Expansion factors and 95% CIs by municipality for the entire study period 2016–2021 (B) and during an outbreak year, 2019 (C). Note that 2 clinical sites were located in São Paulo and that Laranjeiras was the municipality closest to the clinical site in Aracaju.

Main Article

1Preliminary results from this study were presented at the American Society for Tropical Medicine and Hygiene annual meeting; November 13–17, 2024, New Orleans, Louisiana, USA.

Page created: February 27, 2026
Page updated: April 06, 2026
Page reviewed: April 06, 2026
The conclusions, findings, and opinions expressed by authors contributing to this journal do not necessarily reflect the official position of the U.S. Department of Health and Human Services, the Public Health Service, the Centers for Disease Control and Prevention, or the authors' affiliated institutions. Use of trade names is for identification only and does not imply endorsement by any of the groups named above.
file_external